Regenerative Approach for Autoimmune Diseases
- Written by
- StemCell Longevita Editorial Team
- Medically reviewed by
- Prof. Dr. Erdal Karaöz TeamProfessor of Histology and Embryology · Medical Director, Center for Regenerative Medicine
- Last reviewed
- Next scheduled review
How we evaluate evidence · Conflict-of-interest disclosure · Editorial standards
Modulate your immune system and reduce chronic inflammation with advanced mesenchymal regenerative medicine approach. Achieve lasting remission from autoimmune conditions at StemCell Longevita Istanbul.
Can stem cell therapy help autoimmune conditions?
Mesenchymal stem cell therapy is not an approved treatment for autoimmune disease as a category. MSCs have immunomodulatory properties studied in specific conditions, but efficacy varies by disease, protocol and patient. Disease-modifying therapy — DMARDs, biologics, targeted immunosuppression — remains the evidence-based mainstay. Any regenerative option here is considered only alongside a rheumatology or immunology plan, never as replacement.
Key facts
- Approval status
- Not approved as an autoimmune-disease category treatment
- Evidence
- Varies substantially by specific condition
- Standard care
- DMARDs, biologics, targeted immunosuppression under specialist care
What we know
- MSC administration has been studied across several autoimmune indications with short-term safety generally reported as acceptable.
What remains uncertain
- Which autoimmune disease, phenotype or activity level, if any, benefits from MSC administration.
Medically reviewed questions
This summary is general medical information, not medical advice, and not a promise of benefit. Figures are quoted ranges, confirmed in writing after a medical review.
Medically reviewed by: Prof. Dr. Erdal Karaöz · Last updated: · Editorial and evidence policy
Evidence at a glance — Autoimmune disease (general)
A plain summary of what the published research does and does not show for this condition. It is written to the same standard whether the evidence is strong or weak.
- Human studies available?
- Yes — early-stage only
- Randomised trials?
- Randomised evidence is disease-specific; there is no general autoimmune indication
- Main outcomes studied
- Disease-specific activity scores
- Immunosuppressant dose
- Flare frequency
- Safety
- Long-term evidence
- Very limited
- Regulatory approval for this indication
- United States (FDA): No FDA-approved mesenchymal stem cell product for this indication. The FDA has issued consumer warnings about unapproved stem cell products.
- European Union (EMA): No EMA-authorised mesenchymal stem cell medicine for this indication.
- United Kingdom (MHRA): No MHRA-authorised mesenchymal stem cell medicine for this indication.
- Türkiye (Ministry of Health): In Türkiye, cell therapies are delivered only inside Ministry of Health–licensed centres under the regenerative medicine / advanced therapy regulations, as clinical research or individual (exceptional) use — not as an approved routine treatment for this indication.
- Role at our centre
- Research context — considered only where standard care is exhausted or unsuitable, and never as a replacement for it
What kind of evidence exists
- Mechanism (laboratory): Documented
- Animal / preclinical: Documented
- Early human (phase 1/2, uncontrolled): Documented
- Controlled human (randomised or sham-controlled): Documented
- Regulatory approval: Not established
Sources
- Systematic reviews and meta-analyses — Autoimmune disease (general) — PubMed
- Randomised controlled trials — Autoimmune disease (general) — PubMed
- Registered MSC trials — Autoimmune disease (general) — ClinicalTrials.gov
- FDA — Consumer alert on regenerative medicine therapies — U.S. Food and Drug Administration, 2024
- Advanced therapy medicinal products: overview — European Medicines Agency, 2025
- ISSCR Guidelines for Stem Cell Research and Clinical Translation — International Society for Stem Cell Research, 2021
- ISSCR Patient Handbook on Stem Cell Therapies — International Society for Stem Cell Research, 2020
Source links open filtered searches of PubMed and ClinicalTrials.gov plus regulator and professional-society pages, so you can read the current evidence yourself rather than a selected extract.
This summary is general information about the evidence base, not medical advice and not a promise of benefit. Whether any treatment is appropriate for you can only be decided after a medical review of your records.
What are Autoimmune Diseases?
Autoimmune diseases occur when the immune system mistakenly attacks the body's own healthy tissues. This misdirected immune response causes chronic inflammation, tissue damage, and organ dysfunction. There are over 80 recognized autoimmune conditions, affecting an estimated 5–8% of the global population.
Conventional treatments typically rely on immunosuppressive medications that broadly dampen the immune system, often causing significant side effects and increased infection susceptibility. Mesenchymal regenerative medicine approach offers a more targeted approach by modulating — rather than suppressing — the immune system.
Our MSC treatment works by restoring immune balance, reducing the production of autoantibodies, and promoting regulatory T-cell function. This approach addresses the root cause of autoimmune dysfunction while preserving the body's ability to fight infections.
Autoimmune Conditions Responsive to Regenerative Approach
MSC therapy has demonstrated therapeutic benefit across a wide spectrum of autoimmune diseases by addressing the underlying immune dysregulation.
Rheumatoid Arthritis
MSCs reduce joint inflammation, prevent cartilage destruction, and modulate the autoimmune attack on synovial tissue.
Lupus (SLE)
Stem cells are studied for their effect on immune tolerance, reduce autoantibody production, and protect organs from immune-mediated damage.
Multiple Sclerosis
MSCs promote remyelination, reduce neuroinflammation, and modulate the immune attack on the central nervous system.
Crohn's & Colitis
Stem cells are studied for their effect on intestinal inflammation, mucosal healing and immune balance in the gut.
Psoriasis & Scleroderma
MSCs modulate the overactive immune response in skin, reducing inflammation and promoting healthy tissue regeneration.
Hashimoto's & Graves' Disease
Stem cells help regulate thyroid autoimmunity, reducing antibody attacks on thyroid tissue and improving hormone balance.
Understanding the regenerative approach for autoimmune conditions
Autoimmune conditions differ substantially in activity, treatment, and risk. The team reviews diagnosis, medication, recent disease activity, infection risk, and specialist documentation before discussing suitability.
This page is for information and does not replace advice from your usual specialist. Eligibility, delivery route, and follow-up are determined only after an individual medical review.
Who may be considered?
Autoimmune conditions vary widely, so candidacy depends on diagnosis, disease activity, current medication, and specialist records:
- Patients with a confirmed autoimmune diagnosis and current specialist documentation
- People whose symptoms or disease activity remain difficult to manage with standard care
- Patients seeking an individually assessed regenerative approach alongside—not instead of—their rheumatology or specialist care
- Those able to provide recent blood work, imaging, medication lists, and treatment history for review
How the clinical pathway is planned
The recommended plan is individualised after records are reviewed; it is not a fixed, one-size-fits-all treatment package.
- 1
Remote medical-record review
The team reviews diagnosis, history, imaging or test results, current medication, and the goals you want to discuss.
- 2
Clinical suitability assessment
A clinician considers whether a regenerative approach can be discussed safely, including the delivery route and the need for any further testing.
- 3
Written plan before travel
If appropriate, you receive a written outline of the proposed approach, expected visit schedule, exclusions, and coordination arrangements.
- 4
In-person confirmation and follow-up
The plan is reconfirmed after an in-person assessment in Istanbul, with remote follow-up arranged after the visit.
What the approach is intended to address
Immunomodulatory mechanisms are an area of research, not a promise of disease control. Plans must be considered alongside the patient's existing rheumatology or specialist care.
Evidence and outcomes vary by diagnosis, disease stage, delivery approach, and the individual. The consultation is the place to discuss what is known, what remains uncertain, and whether an approach is appropriate for you.
Expected timeline and follow-up
Immune and symptom changes vary by diagnosis and baseline disease activity and cannot be guaranteed. Rather than promising remission, the pathway is built around defined measures and monitoring:
- 1
Pre-treatment review and baseline measures
Medical records, current medication, disease activity, and infection screening are reviewed before a protocol is considered. Relevant baseline measures — such as diagnosis-specific disease-activity scores, CRP, ESR, other inflammatory blood markers, and current medication burden — are agreed with your specialist so change can be assessed objectively.
- 2
Treatment & monitoring
The in-person plan is confirmed in Istanbul, with monitoring around the recommended delivery approach, including infection watch and any specialist-advised laboratory checks.
- 3
Structured remote follow-up
Progress is reviewed against the agreed baseline measures — symptom and diagnosis-specific disease-activity tracking, CRP, ESR or other inflammatory markers where relevant, and medication requirements — and patients are encouraged to continue coordination with their home rheumatology or specialist team.
When treatment may not be appropriate
While MSC therapy is safe for most patients, certain conditions may be contraindications. Treatment is not suitable in the following situations:
- Active cancer or ongoing chemotherapy/radiation treatment
- Active systemic infections requiring IV antibiotics
- Severe organ failure (end-stage kidney, liver, or heart failure)
- Pregnancy or planned pregnancy within 3 months
- Known allergy to any component used in cell processing
- An uncontrolled autoimmune flare requiring urgent conventional treatment
Our medical team conducts a thorough screening process to identify any contraindications before treatment. If stem cell therapy is not appropriate for your situation, we will advise you honestly.
Questions to discuss before deciding
Travel and care-coordination path
Treatment at StemCell Longevita is an all-inclusive medical-travel program from your first consultation to your 12-month follow-up:
- 1
Free online consultation & medical record review
Your journey begins with a free remote consultation. Our medical team reviews your medical records, imaging, and history to assess suitability — no travel required at this stage.
- 2
Written personalized protocol & treatment plan
You receive a written, personalized treatment protocol and plan detailing the recommended cell dosing, delivery route, and expected schedule for your condition.
- 3
Travel booking with clinic assistance
Our team assists with your travel arrangements. Every package includes VIP airport transfer and a 5-star hotel stay with breakfast included for you and an accompanying family member.
- 4
On-arrival medical evaluation in Istanbul
On arrival you undergo an in-person medical evaluation at the JCI-accredited Liv Hospital Ulus in Istanbul before treatment begins.
- 5
Treatment days
Treatment is administered over your stay, with a typical total stay of 3-5 days including evaluation, treatment, and monitoring.
- 6
Return home & 12-month telemedicine follow-up
After returning home you receive a 12-month telemedicine follow-up program with regular remote check-ins to track your progress.
How Stem Cells Work for Autoimmune Diseases
MSC therapy for autoimmune diseases works by modulating the dysregulated immune system rather than broadly suppressing it. Clinical studies suggest that MSCs can restore immune tolerance, reduce autoantibody production, and repair tissue damage caused by chronic autoimmune inflammation, offering a fundamentally different approach from conventional immunosuppressive drugs.
MSCs suppress autoreactive T-cells and B-cells that mistakenly attack the body's own tissues, while simultaneously promoting the development of regulatory T-cells (Tregs). This rebalancing of the immune system helps re-establish immune tolerance, reducing the autoimmune attack without compromising the body's ability to fight infections.
MSCs secrete anti-inflammatory cytokines including IL-10, TGF-B, and prostaglandin E2 (PGE2) that reduce chronic systemic inflammation, a hallmark of autoimmune conditions. Clinical research indicates this anti-inflammatory action can decrease disease activity scores and reduce the frequency and severity of autoimmune flares.
By modulating B-cell function and plasma cell differentiation, MSCs help reduce the production of pathogenic autoantibodies that drive tissue destruction in conditions such as lupus, rheumatoid arthritis, and Hashimoto's thyroiditis. This targeted immunomodulation addresses a root cause of autoimmune damage.
MSCs migrate to sites of tissue damage caused by autoimmune attack and release growth factors that promote tissue repair and regeneration. This dual action of immune modulation combined with tissue repair distinguishes MSC therapy from conventional treatments that only manage symptoms without addressing underlying damage.
Who Is a Good Candidate?
Candidacy for autoimmune the regenerative approach is determined through thorough immunological evaluation, including autoantibody panels, inflammatory markers, organ function assessments, and disease activity scoring. Our immunology specialists evaluate each patient to ensure safe and effective treatment.
Ideal Candidates
- Patients with autoimmune conditions such as lupus, rheumatoid arthritis, or Crohn's disease who have not achieved adequate remission with conventional disease-modifying therapies (DMARDs or biologics)
- Individuals experiencing significant side effects from long-term immunosuppressive medications who seek a treatment approach that modulates rather than suppresses their immune system
- Patients with multiple autoimmune conditions (polyautoimmunity) who may benefit from the broad immunomodulatory effects of MSC therapy across multiple disease pathways
- Individuals with early-stage autoimmune disease who want to pursue proactive treatment before significant organ damage occurs
- Patients with autoimmune-related fatigue, chronic pain, and reduced quality of life who have not responded adequately to standard management protocols
May Not Be Suitable
- Patients with active, severe autoimmune flares requiring immediate high-dose immunosuppression or hospitalization for disease stabilization
- Individuals with active infections, tuberculosis, or hepatitis that must be treated and resolved before immunomodulatory regenerative approaches may be considered
- Patients with active malignancy or undergoing active cancer treatment, as MSC therapy requires oncological clearance
- Individuals with severe organ failure (end-stage renal, hepatic, or cardiac) secondary to autoimmune damage that requires organ-specific intervention as a priority
What Results Can You Expect?
The immunomodulatory effects of MSC therapy for autoimmune diseases develop progressively as the stem cells recalibrate the immune system. Results vary based on the specific autoimmune condition, disease duration, and baseline disease activity.
Initial Recovery
The IV infusion is well-tolerated with minimal downtime. Some patients may experience a temporary mild increase in symptoms as the immune system begins to recalibrate, which typically resolves quickly.
Early Improvements
Many patients begin to notice reductions in joint pain, fatigue, and general inflammation. Initial improvements in inflammatory markers such as CRP and ESR may become measurable on blood testing.
Progressive Results
More significant improvements in disease activity scores are commonly observed. Patients often report reduced frequency of flares, decreased medication requirements, and improved energy and functional capacity.
Optimal Results
Peak immunomodulatory effects are typically achieved, with measurable reductions in autoantibody levels and inflammatory markers. Many patients experience sustained disease remission or significantly reduced disease activity.
Long-Term Benefits
The immune-rebalancing effects of MSC therapy can persist for months to years. Some patients achieve lasting remission, while others benefit from periodic follow-up treatments to maintain immune stability.
Individual results vary. These timelines are based on clinical observations and are not guaranteed outcomes. Your specialist will provide personalized expectations during your consultation.
How the Regenerative Approach Is Intended to Work in Autoimmune Disease
MSCs employ multiple mechanisms to restore immune balance and reduce the autoimmune attack on healthy tissues.
Immune System Modulation
MSCs suppress overactive T-cells and B-cells while promoting the development of regulatory T-cells that maintain immune tolerance.
Inflammation Reduction
Stem cells secrete anti-inflammatory cytokines that reduce chronic inflammation throughout the body, addressing a key driver of autoimmune damage.
Tissue Repair & Regeneration
MSCs migrate to sites of tissue damage caused by autoimmune attack, promoting repair and regeneration of affected organs and tissues.
Autoantibody Reduction
By modulating B-cell function, MSCs help reduce the production of autoantibodies that mistakenly target healthy tissues.
Long-Term Immune Balance
The immunomodulatory effects of MSCs can persist for months after treatment, providing sustained immune recalibration and reduced disease activity.
Reduced Medication Dependency
Many patients experience sufficient improvement to gradually reduce their immunosuppressive medications under medical supervision.
Why Choose Regenerative Approach for Autoimmune Disease?
MSC therapy offers a fundamentally different approach to autoimmune treatment, targeting the cause rather than just suppressing symptoms.
Immune Rebalancing
MSCs modulate rather than suppress the immune system, restoring proper immune function while preserving the body's defense against infections.
Tissue Regeneration
Stem cells promote the repair of tissues damaged by chronic autoimmune inflammation, restoring organ function and reducing symptoms.
Reduced Flare-Ups
By addressing the underlying immune dysregulation, MSC therapy can significantly reduce the frequency and severity of disease flares.
Targeted Treatment
MSCs naturally home to areas of inflammation and tissue damage, delivering targeted therapeutic effects where they are needed most.
Patient Experiences
Real outcomes from patients who chose regenerative medicine at StemCell Longevita Istanbul
"My rheumatologist was surprised by the improvement. I can hold my grandchildren's hands again without wincing — that means everything to me."
"Lupus controlled my life for a decade. After treatment in Istanbul, I travelled to three countries in one month — something unimaginable a year ago."
Watch Our Patient Stories & Expert Insights
See real results and hear from our medical team about stem cell therapy treatments, procedures, and patient outcomes.
All Regenerative Medicine Applications
Explore our comprehensive range of regenerative medicine applications for various conditions. Click any option to learn more.
Related Articles
Explore our in-depth research articles and guides on related treatments and therapies.
Regenerative Approaches for Autoimmune Conditions: Research & Outcomes
Research on how mesenchymal stem cell approaches modulate the immune system to address autoimmune conditions including lupus, rheumatoid arthritis, and Crohn's disease.
Read ArticleUnderstanding Regenerative Medicine: A Complete Guide
A comprehensive overview of stem cell therapy, including types of stem cells, care processes, safety considerations, and what patients can expect during their wellness journey.
Read ArticleExosome Therapy: The Next Frontier in Regenerative Medicine
Learn about exosome therapy and how these powerful cellular messengers are being studied to support tissue repair, reduce inflammation, and support overall wellness processes.
Read ArticleHow Much Does This Cost Worldwide?
Compare this regenerative medicine costs at StemCell Longevita versus clinics in other countries.
| Country | Typical Cost |
|---|---|
| United States | $20,000 – $35,000 |
| United Kingdom | £15,000 – £28,000 |
| Germany | €18,000 – €32,000 |
| South Korea | $15,000 – $25,000 |
| StemCell Longevita (Turkey) | From £7,600 |
Prices based on market research of comparable stem cell clinics offering umbilical cord-derived MSC treatments (2025-2026). Actual prices vary by clinic, cell count, and condition.
Related clinical questions
Where this page sits in the wider picture.